You just read:

EPIGENE THERAPEUTICS INC. announces presentation on NEO2734, an oral dual inhibitor of both BET and CBP-P300, at the 2019 Genitourinary Cancers Symposium

News provided by

Epigene Therapeutics Inc.

Feb 11, 2019, 09:40 ET